Over-the-counter medicines, products that can be sold to the public without a prescription occupy a distinctive position in the pharmaceutical regulatory landscape. They reflect a public health judgment that certain medicines, used for common and self-limiting conditions, can be safely used by patients with the support of pharmacist counseling rather than prescriber supervision. The OTC category sits at the intersection of public health policy, consumer behavior, and commercial strategy, and the legal framework around it in Iraq reflects this complex position.
Classification
Classification of a medicine as OTC or prescription-only is made by the Ministry of Health during the registration process or by later reclassification. The decision considers the active ingredient, indication, dosage form, strength, safety profilewhen used without medical supervision, and risk profilefor self-administration. The classification is not just a label; it determines distribution channels, advertising rules, pricing approach, and a range of commercial and regulatory consequences. A product classified as prescription-only is positioned very differently from the same product classified as OTC, and the regulatory pathway for switching between categories is itself a significant commercial undertaking.
OTC medicines in Iraq are generally distributed through licensed pharmacies. The pharmacist remains an important resource for advice on OTC selection and use, even though a prescription is not required. Sale of medicines outside licensed pharmacies, general stores, kiosks, online platforms not authorized for pharmaceutical sales is generally not permitted, and unauthorized retail of medicines is a regulatory offense regardless of whether the medicines themselves are OTC or prescription-only.
Labeling
Labeling and patient information for OTC products must be clear, accessible to non-specialist users, and consistent with the approved product information. Approved Arabic labeling is required, including information on indications, dosing, warnings, contraindications, and when to consult a doctor. Patient leaflets are written in plain language. Particular attention is paid to identifying populations who should not take the product without medical advice, including pregnant women, children, the elderly, and patients with specific medical conditions. The labeling is, in many cases, the principal source of safety information for OTC users, and the regulator scrutinizes it accordingly.
Advertising to the Public
Advertising of OTC medicines is permitted but subject to specific rules. Advertising materials must be reviewed and approved by the Ministry of Health, must be accurate and not misleading, and must be consistent with the approved product information. Advertising must not encourage excessive or inappropriate consumption. Endorsement by healthcare professionals is typically prohibited in OTC advertising, and references to scientific evidence are restricted to ensure that promotion does not blur into clinical claims that go beyond what the regulator has approved.
Different media carry different rules. Television and radio have defined disclosure requirements and limits on the time and content of pharmaceutical advertisements. Print media advertising must respect rules on testimonials, before-and-after claims, and prohibited claims about serious diseases. Digital and social media advertising is subject to the same rules, although the practical mechanisms of enforcement are still developing, and influencer marketing of OTC products in particular requires careful compliance structuring.
Pricing
Pricing of OTC medicines, like prescription medicines, is regulated in Iraq. The Ministry of Health approves prices, and distribution margins are set for wholesale and retail. Promotional discounts and consumer pricing offers are subject to limits to maintain the integrity of the pricing system. Bundling and combination offers should be reviewed against pricing regulation to ensure that they do not effectively undermine the regulated price structure.
Common OTC Categories
Common OTC categories in Iraq include analgesics and antipyretics, antacids, cough and cold remedies, topical preparations, and vitamins and supplements where regulated as medicines. Each category has its own considerations. Pediatric formulations require additional warnings and dosing precautions; products with potential for abuse or misuse may carry enhanced controls including limits on pack size or pharmacy oversight; antibiotics, even though prescription-only, attract specific concern in Iraq given the public health risks of over-the-counter sale and antimicrobial resistance; an issue the Ministry of Health and the Pharmacists Syndicate continue to address through enforcement.
Rx-to-OTC Switches
Switching a product from prescription status to OTC status is an important regulatory and commercial event. Such switches require evidence that the product can be safely used without medical supervision for the relevant indication and population. The supporting evidence typically includes the post-marketing safety database, consumer comprehension studies showing that lay users can understand the labeling and use the product correctly, and risk minimization plans where appropriate. Switching significantly expands market access; OTC products can be promoted to the public and dispensed without prescription but also imposes new responsibilities on the company in safety communication and labeling.
Pharmacist’s Role
Pharmacists play a critical role in OTC use. The pharmacist’s professional duty includes advising on product selection, counseling on use, dosing, and risks, recognizing cases that should be referred to a physician, and identifying and reporting adverse events. Pharmaceutical companies can support this role through training, scientific information, and quality educational materials, but all of these activities are subject to the same promotional regulations that govern prescription medicines.
Self-Medication
Patient self-medication is a recognized public health phenomenon with both benefits and risks. It provides convenient access to treatment for minor conditions and reduces the burden on the healthcare system, but it can also lead to misdiagnosis, inappropriate product selection, delays in seeking medical care for serious conditions, adverse interactions, and overuse. The regulatory framework through classification decisions, labeling, advertising rules, and pharmacy distribution attempts to balance these considerations, but it depends on cooperation between manufacturers, pharmacists, and patients to function effectively.
Pharmacovigilance for OTC
Pharmacovigilance obligations apply to OTC products as they do to prescription medicines, with some practical differences. Marketing authorization holders must maintain pharmacovigilance systems, submit adverse event reports and periodic safety reports, and identify signals that may emerge from broader population exposure. The pharmacovigilance challenge for OTC products is real: use is more widespread and less supervised than for prescription medicines, and real-world use patterns often differ from the labeled uses, with a higher proportion of use in special populations such as the elderly and the multi-medicated.
Compliance for OTC Companies
Companies marketing OTC products in Iraq should establish compliance programs that cover product classification status, labeling compliance, advertising review and approval, monitoring of promotional activities, pharmacovigilance, and the documentation supporting any switch applications. The OTC space tends to be commercially attractive because of the broader market access it permits, but it carries its own regulatory disciplines, and companies that approach it as a less-regulated version of prescription medicine marketing tend to encounter compliance issues that they did not anticipate.
How We Can Help
Etihad Law Firm advises pharmaceutical companies on the regulatory and commercial aspects of OTC medicines in Iraq, including classification matters, switch applications, labeling and advertising compliance, distribution arrangements, and regulatory disputes.